These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29378733)

  • 1. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
    Echavarria I; López-Tarruella S; Picornell A; García-Saenz JÁ; Jerez Y; Hoadley K; Gómez HL; Moreno F; Monte-Millan MD; Márquez-Rodas I; Alvarez E; Ramos-Medina R; Gayarre J; Massarrah T; Ocaña I; Cebollero M; Fuentes H; Barnadas A; Ballesteros AI; Bohn U; Perou CM; Martin M
    Clin Cancer Res; 2018 Apr; 24(8):1845-1852. PubMed ID: 29378733
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
    Sharma P; López-Tarruella S; García-Saenz JA; Khan QJ; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Monte-Millán MD; González-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortés J; Fuentes-Rivera H; Morales DB; Márquez-Rodas I; Perou CM; Lehn C; Wang YY; Klemp JR; Mammen JV; Wagner JL; Amin AL; O'Dea AP; Heldstab J; Jensen RA; Kimler BF; Godwin AK; Martín M
    Clin Cancer Res; 2018 Dec; 24(23):5820-5829. PubMed ID: 30061361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
    Sharma P; López-Tarruella S; García-Saenz JA; Ward C; Connor CS; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Del Monte-Millán M; Gonzalez-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortes J; Fuentes Rivera H; Bretel Morales D; Márquez-Rodas I; Perou CM; Wagner JL; Mammen JM; McGinness MK; Klemp JR; Amin AL; Fabian CJ; Heldstab J; Godwin AK; Jensen RA; Kimler BF; Khan QJ; Martin M
    Clin Cancer Res; 2017 Feb; 23(3):649-657. PubMed ID: 27301700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
    Kaklamani VG; Jeruss JS; Hughes E; Siziopikou K; Timms KM; Gutin A; Abkevich V; Sangale Z; Solimeno C; Brown KL; Jones J; Hartman AR; Meservey C; Jovanovic B; Helenowski I; Khan SA; Bethke K; Hansen N; Uthe R; Giordano S; Rosen S; Hoskins K; Von Roenn J; Jain S; Parini V; Gradishar W
    Breast Cancer Res Treat; 2015 Jun; 151(3):629-38. PubMed ID: 26006067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
    Masuda H; Baggerly KA; Wang Y; Zhang Y; Gonzalez-Angulo AM; Meric-Bernstam F; Valero V; Lehmann BD; Pietenpol JA; Hortobagyi GN; Symmans WF; Ueno NT
    Clin Cancer Res; 2013 Oct; 19(19):5533-40. PubMed ID: 23948975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
    Kern P; Kalisch A; von Minckwitz G; Pütter C; Kolberg HC; Pott D; Kurbacher C; Rezai M; Kimmig R
    J Chemother; 2016 Jun; 28(3):210-7. PubMed ID: 26239282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response.
    Kern P; Kalisch A; Kolberg HC; Kimmig R; Otterbach F; von Minckwitz G; Sikov WM; Pott D; Kurbacher C
    Chemotherapy; 2013; 59(5):387-94. PubMed ID: 24852315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
    Zhang L; Wu ZY; Li J; Lin Y; Liu Z; Cao Y; Zhang G; Gao HF; Yang M; Yang CQ; Zhu T; Cheng MY; Ji F; Li J; Wang K
    Int J Cancer; 2022 Feb; 150(4):654-662. PubMed ID: 34591977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
    Ring BZ; Hout DR; Morris SW; Lawrence K; Schweitzer BL; Bailey DB; Lehmann BD; Pietenpol JA; Seitz RS
    BMC Cancer; 2016 Feb; 16():143. PubMed ID: 26908167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
    Gerber B; Loibl S; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Nekljudova V; Untch M; von Minckwitz G;
    Ann Oncol; 2013 Dec; 24(12):2978-84. PubMed ID: 24136883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
    Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
    Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
    Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
    Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
    Telli ML; Jensen KC; Vinayak S; Kurian AW; Lipson JA; Flaherty PJ; Timms K; Abkevich V; Schackmann EA; Wapnir IL; Carlson RW; Chang PJ; Sparano JA; Head B; Goldstein LJ; Haley B; Dakhil SR; Reid JE; Hartman AR; Manola J; Ford JM
    J Clin Oncol; 2015 Jun; 33(17):1895-901. PubMed ID: 25847929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
    Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
    Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.